Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy
- PMID: 22176145
- DOI: 10.1111/j.1529-8027.2011.00365.x
Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy
Abstract
Fabry disease (FD) is an X-linked lysosomal storage disorder which may lead to impaired peripheral nerve function, mostly affecting small nerve fibers, and to neuropathic pain. Characteristics of the neuropathy associated with FD and the covariates for its development and temporal course have not been described in a large cohort. We studied small fiber function and morphology in 120 Fabry patients at baseline and in subgroups of these until 4-year follow-up. Baseline neurological (89/120) and electrophysiological (106/120) examination was mostly normal. Quantitative sensory testing revealed impaired cold detection thresholds in 84% of men and 39% of women. Lower leg intraepidermal nerve fiber density (IENFD) was reduced to 46% in Fabry patients compared to controls and to 12.5% in men with impaired renal function. Patients with abnormal IENFD more often had pain. Group means for IENFD did not improve under enzyme replacement therapy (ERT), but IENFD in the back increased under ERT in 4/15 patients with good renal function and clinical improvement. Cutaneous cytokine gene expression did not differ from controls. We conclude that ERT may improve proximal skin innervation in patients with good renal function, but does not protect small fiber function in men with impaired renal function.
© 2011 Peripheral Nerve Society.
Similar articles
-
Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.Pain. 2009 Sep;145(1-2):237-45. doi: 10.1016/j.pain.2009.06.032. Epub 2009 Aug 7. Pain. 2009. PMID: 19665302 Clinical Trial.
-
Enzyme replacement therapy and intraepidermal innervation density in Fabry disease.Muscle Nerve. 2006 Jul;34(1):53-6. doi: 10.1002/mus.20550. Muscle Nerve. 2006. PMID: 16583374 Clinical Trial.
-
Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.Muscle Nerve. 2003 Dec;28(6):703-10. doi: 10.1002/mus.10497. Muscle Nerve. 2003. PMID: 14639584 Clinical Trial.
-
Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.Acta Neurol Belg. 2006 Jun;106(2):61-5. Acta Neurol Belg. 2006. PMID: 16898255 Review.
-
Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.Acta Neurol Scand. 2012 Aug;126(2):77-97. doi: 10.1111/j.1600-0404.2012.01661.x. Epub 2012 Mar 19. Acta Neurol Scand. 2012. PMID: 22428782 Review.
Cited by
-
Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.Mol Pain. 2016 May 4;12:1744806916646379. doi: 10.1177/1744806916646379. Print 2016. Mol Pain. 2016. PMID: 27145802 Free PMC article.
-
No Fabry Disease in Patients Presenting with Isolated Small Fiber Neuropathy.PLoS One. 2016 Feb 11;11(2):e0148316. doi: 10.1371/journal.pone.0148316. eCollection 2016. PLoS One. 2016. PMID: 26866599 Free PMC article.
-
Small fiber pathology in fibromyalgia syndrome.Pain Rep. 2024 Dec 24;10(1):e1220. doi: 10.1097/PR9.0000000000001220. eCollection 2025 Feb. Pain Rep. 2024. PMID: 39726855 Free PMC article. Review.
-
C-Fiber Assays in the Cornea vs. Skin.Brain Sci. 2019 Nov 12;9(11):320. doi: 10.3390/brainsci9110320. Brain Sci. 2019. PMID: 31718074 Free PMC article. Review.
-
Age-related neuroimmune signatures in dorsal root ganglia of a Fabry disease mouse model.Immun Ageing. 2023 May 12;20(1):22. doi: 10.1186/s12979-023-00346-8. Immun Ageing. 2023. PMID: 37173694 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical